CureVac COVID-19 vaccine

From Simple English Wikipedia, the free encyclopedia
Jump to navigation Jump to search

The CureVac COVID-19 vaccine is a COVID-19 vaccine candidate created by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI).[1]

The vaccine showed bad results in its Phase III trials with only 47% effective.[2]

References[change | change source]

  1. "CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide". Press release. 15 March 2020. https://www.curevac.com/en/2020/03/15/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide/. Retrieved 17 February 2021. 
  2. Burger, Ludwig (2021-06-16). "CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy". Reuters. Retrieved 2021-06-17.